Journal
JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL
Volume 33, Issue 26B, Pages 36-41Publisher
SCIENCEDOMAIN INT
DOI: 10.9734/JPRI/2021/v33i26B31480
Keywords
COVID-19; heterologous immunity; SARS-CoV; MERS-CoV; and SARS-CoV-2
Categories
Funding
- Scientific Research Deanship at University of Ha'il - Saudi Arabia [COVID-1940]
Ask authors/readers for more resources
COVID-19 has spread abnormally compared to other beta-coronaviruses, affecting over 130 million humans. The study aims to compare the genomic and proteomic characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2, and their potential cross-immunity for prevention and treatment of COVID-19.
COVID-19 spreads abnormally compared to its counterparts in the same family beta-coronaviruses. Today, we count more than 130 million affected humans affected by the COVID-19. Therefore, the study of means of prevention and treatment is an urgent need. Interestingly, the novel virus (SARS-CoV-2) has some similarities with SARS-CoV and MERS-CoV. It is known that heterologous immunity is well recognized within species of the same family. The use of previously recognized effective antibodies for SARS and MERS virus may prevent the COVID-19 pandemic. The objective of this study is to compare between SARS-CoV, MERS-CoV, and SARS-CoV-2 genomic and proteomic identity/similarity and their cross-immunity as well as their immunological features in the context of COVID-19 diseases prevention and treatment methods.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available